Recursion Pharmaceuticals, Inc.
RXRX · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2018–FY2025
- History
- 8 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Recursion Pharmaceuticals, Inc. at a glance
In FY2025, Recursion Pharmaceuticals, Inc. reported revenue of USD 74,681 thousands, EBITDA of USD -586,680 thousands, free cash flow of USD -378,277 thousands.
| USD thousands | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 58,839 | 74,681 | |||
| EBITDA | -459,126 | -586,680 | |||
| Free cash flow | -372,869 | -378,277 | |||
| ROIC | 0.0% | 0.0% |
The full 8-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas